An observational study in Compensatory Hyperhidrosis and Compensatory Sweating, sponsored by Assiut University. Not yet recruiting. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Assiut University · Observational
The goal of this study is to compare the proportion of compensatory hyperhidrosis patients after sympathectomy at T3 level and sympathectomy at T3-4 level. The main question it aims to answer is:
can sympathectomyv at one level decrease the incidence of compensatory hyperhidrosis after primary hyperhidrosis.
Primary hyperhidrosis is a chronic condition characterized by excessive sweating beyond physiological needs, commonly affecting the palms, axillae, face, or soles. This disorder is largely attributed to neurogenic hyperexcitability within the sympathetic nervous system's pathways innervating the eccrine sweat glands.When conservative treatments such as topical agents or oral medications fail, endoscopic thoracic sympathectomy (ETS) is considered an effective surgical option. However, a major postoperative complication is compensatory hyperhidrosis (CH)-the development of excessive sweating in previously unaffected areas such as the trunk, back, or thighs. CH can significantly impact patient satisfaction and quality of life, often becoming more distressing than the original condition.
The extent and level of sympathectomy have been proposed as key factors influencing the incidence and severity of CH. While higher levels or multilevel resections (e.g., T2-4) are associated with increased rates of CH, more limited approaches such as T3-only resection are thought to reduce this risk. However, definitive evidence comparing T3 versus T3-4 sympathectomy remains limited and inconsistent across studies.
This study aims to compare the incidence and severity of compensatory hyperhidrosis following T3 versus T3-4 sympathectomy for primary hyperhidrosis. Understanding these differences may help refine surgical approaches to minimize CH and improve patient outcomes.
111 studies on the registry are indexed under Hyperhidrosis; 10 are open to participants now.
Browse Hyperhidrosis studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
population of study are patients with primary hyperhidrosis who are going through T3 or T3-4 sympathectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients who underwent T3 sympathectomy for primary hyperhidrosis
patients who underwent through T3-4 sympathectomy for primary hyperhidrosis
To compare the incidence of compensatory hyperhidrosis following T3 versus T3-4 sympathectomy.
Time frame: 1 year post-sympathectomy
severity of Compensatory hyperhidrosis by hyperhidrosis disease severity scale
1. The sweating is never noticeable and doesn't interfere with daily activities. 2. The sweating is tolerable but sometimes interferes with daily activities. 3. The sweating is barely tolerable and frequently interferes with daily activities. 4. The sweating is intolerable and always interferes with daily activities.
Time frame: 1 year post sympathectomy
recurrence rates of primary hyperhidrosis
Time frame: 1 year post sympathectomy
site of compensatory hyperhidrosis
Time frame: 1year post sympathectomy
No study locations are listed for this record.
Start is estimated for Nov 2025; primary completion for Oct 2027, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.